Cited by 1,357RNA Interference and Gene DeliveryVirus-based gene therapy researchRNA Research and Splicing

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

RNAi-mediated gene silencing in non-human primates

Zimmermann, Tracy S., Lee, Amy C. H., Akinc, Akin, Bramlage, Birgit, Bumcrot, David, Fedoruk, Matthew N., Harborth, Jens, Heyes, James A., Jeffs, Lloyd B., John, Matthias, Judge, Adam D., Lam, Kieu, McClintock, Kevin, Nechev, Lubomir V., Palmer, Lorne R., Racie, Timothy, Röhl, Ingo, Seiffert, Stephan, Shanmugam, Sumi, Sood, Vandana, Soutschek, Jürgen, Toudjarska, Ivanka, Wheat, Amanda J., Yaworski, Ed, Zedalis, William, Koteliansky, Victor, Manoharan, Muthiah, Vornlocher, Hans-Peter, MacLachlan, Ian·2006·Nature

DOI 10.1038/nature04688

Open this paper in CoChat — free account

Abstract

The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing genes holds great promise for the development of therapeutics directed against targets that are otherwise not addressable with current medicines. Although there are numerous examples of in vivo silencing of target genes after local delivery of small interfering RNAs (siRNAs), there remain only a few reports of RNAi-mediated silencing in response to systemic delivery of siRNA, and there are no reports of systemic efficacy in non-rodent species. Here we show that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B (ApoB) in non-human primates. APOB-specific siRNAs were encapsulated in stable nucleic acid lipid particles (SNALP) and administered by intravenous injection to cynomolgus monkeys at doses of 1 or 2.5 mg kg(-1). A single siRNA injection resulted in dose-dependent silencing of APOB messenger RNA expression in the liver 48 h after administration, with maximal silencing of >90%. This silencing effect occurred as a result of APOB mRNA cleavage at precisely the site predicted for the RNAi mechanism. Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels were observed as early as 24 h after treatment and lasted for 11 days at the highest siRNA dose, thus demonstrating an immediate, potent and lasting biological effect of siRNA treatment. Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.

Integrity signals

Registry

Crossref · 10.1038/nature04688

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
Hornung, V., Guenthner‐Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A. M., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,261
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,027
The RNAi revolution
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 739
Inhibition of respiratory viruses by nasally administered siRNA
Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2004) · Nature Medicine · doi:10.1038/nm1164 · Cited by 731

Flagged first, then by citations

Show all 20 references

Sorted by citations

Items 301–400 of 1,001

Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype
Conceição, M., Mendonça, L., Nóbrega, C., Gomes, C., Costa, P., Hirai, H., Moreira, J. N., Lima, M. C., Manjunath, N., & Pereira de Almeida, L. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.021 · Cited by 117
Liver as a target for oligonucleotide therapeutics
Sehgal, A., Vaishnaw, A. K., & Fitzgerald, K. J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.045 · Cited by 116
“The RNAi therapeutic ALN-PCS, targeting PCSK9, has been evaluated in a phase 1 clinical study (NCT01437059) [4,6,7].”
Method
Suppression of HIV-1 replication by microRNA effectors
Chable-Bessia, C., Méziane, O., Latreille, D., Triboulet, R., Zamborlini, A., Wagschal, A., Jacquet, J., Reynes, J., Lévy, Y., Saı̈b, A., et al. (2009) · Retrovirology · doi:10.1186/1742-4690-6-26 · Cited by 119
Novel Polymerizable Surfactants with pH-Sensitive Amphiphilicity and Cell Membrane Disruption for Efficient siRNA Delivery
Wang, X.-L., Ramusovic, S., Nguyen, T. D., & Lu, Z. (2007) · Bioconjugate Chemistry · doi:10.1021/bc700285q · Cited by 115
Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer
Yuen, J. S. P., & Macaulay, V. M. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.5.589 · Cited by 114
“Stabilised forms of siRNA are capable of inducing effective gene silencing in vivo , and early phase clinical trials are evaluating effects of siRNAs in treating age-related macular degeneration and respiratory syncytial virus [165-167] , although such approaches have not been applied to cancer therapy.”
Background
RNA Mediated toll-like receptor stimulation in health and disease
Dalpke, A. H., & Helm, M. (2012) · RNA Biology · doi:10.4161/rna.20206 · Cited by 113
Non-viral nanosystems for systemic siRNA delivery
David, S., Pitard, B., Benoît, J., & Passirani, C. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.11.013 · Cited by 115
Strategies for targeted nonviral delivery of siRNAs in vivo
Kim, S. S., Garg, H., Joshi, A., & Manjunath, N. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.09.001 · Cited by 115
MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer
Lim, L., Balakrishnan, A., Huskey, N. E., Jones, K. D., Jodari‐Karimi, M., Ng, R., Song, G., Riordan, J. D., Anderton, B. N., Cheung, S., et al. (2013) · Hepatology · doi:10.1002/hep.26662 · Cited by 113
In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas
Amjad, M. W., Amin, M. C. I. M., Katas, H., Butt, A. M., Kesharwani, P., & Iyer, A. K. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00827 · Cited by 111
Glucan particles for selective delivery of siRNA to phagocytic cells in mice
Tesz, G. J., Aouadi, M., Prot, M., Nicoloro, S. M. C., Boutet, E., Amano, S. U., Goller, A., Wang, M., Guo, C., Salomon, W. E., et al. (2011) · Biochemical Journal · doi:10.1042/bj20110352 · Cited by 110
Structure–activity relationships of siRNA carriers based on sequence-defined oligo (ethane amino) amides
Fröhlich, T., Edinger, D., Kläger, R., Troiber, C., Salcher, E. E., Badgujar, N. S., Martín, I., Schaffert, D., Cengizeroglu, A., Hadwiger, P., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.018 · Cited by 110
“different approaches of delivery have shown to be promising, including covalent attachment of cholesterol [8] or peptides [9], antibody-linked siRNA [10,11], liposomes [12], polymers [13–19] and lipid-modified polymer formulations [20–23].”
Background
Site-Specific Antibody–Polymer Conjugates for siRNA Delivery
Lu, H., Wang, D., Kazane, S. A., Javahishvili, T., Tian, F., Song, F., Sellers, A. J., Barnett, B., & Schultz, P. G. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4059525 · Cited by 109
RNA interference therapeutics for cancer: Challenges and opportunities (Review)
Bora, R. S. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.871 · Cited by 123
Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review
Chaturvedi, K., Ganguly, K., Kulkarni, A. R., Kulkarni, V. H., Nadagouda, M. N., Rudzinski, W. E., & Aminabhavi, T. M. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.610790 · Cited by 110
“In addition, stable nucleic acid lipid particles (SNALPs) in the size range of 77 -- 83 nm have been investigated to show a rapid silencing of apoB (apolipoprotein B) gene in the liver of cynomolgus monkey [65].”
Background
Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties
Besin, G., Milton, J., Sabnis, S., Howell, R. D., Mihai, C., Burke, K. E., Benenato, K. E., Stanton, M., Smith, P., Senn, J. J., et al. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900029 · Cited by 108
“We sought to determine if the ABC phenomenon described in the literature (16, 17) occurs with mRNA-LNP.”
Background
Oligonucleotide Therapeutics: Chemistry, Delivery and Clinical Progress
Sharma, V. K., & Watts, J. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.144 · Cited by 112
EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma
Gao, J., Yu, Y., Zhang, Y., Song, J., Chen, H., Li, W., Qian, W., Deng, L., Kou, G., Chen, J., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.035 · Cited by 109
Omics-based nanomedicine: The future of personalized oncology
Rosenblum, D., & Peer, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.029 · Cited by 114
“Several such ‘‘nondruggable’’ molecules have been successfully targeted by RNAi approach in vivo [92–95] demonstrating an exclusively allele-specific gene silencing [95,96].”
Background
Exosome Encased Spherical Nucleic Acid Gold Nanoparticle Conjugates as Potent MicroRNA Regulation Agents
Alhasan, A. H., Patel, P. C., Choi, C. H. J., & Mirkin, C. A. (2013) · Small · doi:10.1002/smll.201302143 · Cited by 108
Functional Nanostructures for Effective Delivery of Small Interfering RNA Therapeutics
Hong, C. A., & Nam, Y. S. (2014) · Theranostics · doi:10.7150/thno.8491 · Cited by 114
Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities
Zhang, J., Shen, H., Xu, J., Liu, L., Tan, J., Li, M., Xu, N., Luo, S., Wang, J., Yang, F., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c02633 · Cited by 108
RNAi-based therapeutic strategies for metabolic disease
Czech, M., Aouadi, M., & Tesz, G. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.57 · Cited by 108
Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway
Sato, Y., Kinami, Y., Hashiba, K., & Harashima, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.006 · Cited by 112
Recent advances in using liposomes for delivery of nucleic acid-based therapeutics
Nsairat, H., Alshaer, W., Odeh, F., Esawi, E., Khater, D., Bawab, A. A., El‐Tanani, M., Awidi, A., & Mubarak, M. S. (2023) · OpenNano · doi:10.1016/j.onano.2023.100132 · Cited by 119
Effect of PEGylation on Biodistribution and Gene Silencing of siRNA/Lipid Nanoparticle Complexes
Bao, Y., Jin, Y., Chivukula, P., Zhang, J., Liu, Y., Liu, J., Clamme, J., Mahato, R. I., Ng, D., Ying, W., et al. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0874-6 · Cited by 107
“A releasable PEG-C14 lipid consisting of a 2 kDa PEG segment was designed for quick release from the LNPs after parenteral injection (20,34).”
Non-viral gene delivery carrier and its three-dimensional transfection system
He, C., Tabata, Y., & Gao, J.-Q. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.11.006 · Cited by 107
“Such an approach has been taken by several groups with varying degrees of success for pulmonary (Li et al., 2008b, 2005) and hepatic metastases (Zimmermann et al., 2006; Jing et al., 2008; Sato et al., 2007).”
DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA
Mével, M., Kamaly, N., Carmona, S., Oliver, M. H., Jorgensen, M. R., Crowther, C. E., Salazar, F. H., Marion, P. L., Fujino, M., Natori, Y., et al. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.001 · Cited by 104
Targeted Delivery Systems of Small Interfering RNA by Systemic Administration
Kawakami, S., & Hashida, M. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.142 · Cited by 104
RNAi: a potential new class of therapeutic for human genetic disease
Seyhan, A. A. (2011) · Human Genetics · doi:10.1007/s00439-011-0995-8 · Cited by 104
Involvement of Epithelial Cell Transforming Sequence-2 Oncoantigen in Lung and Esophageal Cancer Progression
Hirata, D., Yamabuki, T., Miki, D., Ito, T., Tsuchiya, E., Fujita, M., Hosokawa, M., Chayama, K., Nakamura, Y., & Daigo, Y. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1672 · Cited by 102
Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAs In Vivo
Wong, S. C., Klein, J. J., Hamilton, H., Chu, Q., Frey, C. L., Trubetskoy, V. S., Hegge, J., Wakefield, D. H., Rozema, D. B., & Lewis, D. L. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0389 · Cited by 101
“The potency and speciﬁcity of synthetic siRNA has been well established in cultured cell systems as well as in a few animal models (Soutschek et al., 2004; Zimmermann et al., 2006; Rozema et al., 2007; Shegokar et al., 2011).”
Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA
Lin, P. J. C., Tam, Y. Y. C., Hafez, I. M., Sandhu, A. P., Chen, S., Ciufolini, M. A., Nabi, I. R., & Cullis, P. R. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.05.019 · Cited by 101
“LNP systems are also of increasing utility for the in vivo delivery of siRNA.(10,11) The most promising LNP-siRNA systems contain ionizable cationic lipids with pKa values below 7 that allow the LNP to exhibit little positive charge at physiological pH.”
The Business of RNAi Therapeutics in 2012
Haussecker, D. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2011.9 · Cited by 102
Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging
Li, J., Zhao, M., Su, H., Wang, Y., Tan, C., Ji, L., & Mao, Z. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.011 · Cited by 102
Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo
Lin, D., Cheng, Q., Jiang, Q., Huang, Y., Yang, Z., Han, S., Zhao, Y., Guo, S., Liang, Z., & Dong, A. (2013) · Nanoscale · doi:10.1039/c3nr00294b · Cited by 101
Lipid Nanoparticle Technologies for Nucleic Acid Delivery: A Nanoarchitectonics Perspective
Ferhan, A. R., Park, S.-H., Park, H., Tae, H., Jackman, J. A., & Cho, N. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202203669 · Cited by 103
In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery
Golzio, M., Mazzolini, L., Ledoux, A., Paganin-Gioanni, A., Izard, M. E., Hellaudais, L., Bieth, A., Pillaire, M., Cazaux, C., Hoffmann, J., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302920 · Cited by 101
siRNA-Based Therapy Ameliorates Glomerulonephritis
Shimizu, H., Hori, Y., Kaname, S., Yamada, K., Nishiyama, N., Matsumoto, S., Miyata, K., Oba, M., Yamada, A., Kataoka, K., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009030295 · Cited by 104
Id-1 activation of PI3K/Akt/NF B signaling pathway and its significance in promoting survival of esophageal cancer cells
Li, B., Cheung, P. Y., Wang, X., Tsao, S. W., Ling, M. T., Wong, Y. C., & Cheung, A. L. M. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm152 · Cited by 99
Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses
Katakowski, J. A., Mukherjee, G., Wilner, S. E., Maier, K. E., Harrison, M. T., DiLorenzo, T. P., Levy, M., & Palliser, D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.175 · Cited by 100
MicroRNA‐494 is a master epigenetic regulator of multiple invasion‐suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors
Chuang, K., Whitney‐Miller, C. L., Chu, C., Zhou, Z., Dokus, M. K., Schmit, S., & Barry, C. T. (2015) · Hepatology · doi:10.1002/hep.27816 · Cited by 100
Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-Met in regenerating rat livers by RNA interference
Paranjpe, S., Bowen, W. C., Bell, A. W., Nejak-Bowen, K., Luo, J.-H., & Michalopoulos, G. K. (2007) · Hepatology · doi:10.1002/hep.21570 · Cited by 100
RETRACTED: HMGA1 Is a Determinant of Cellular Invasiveness and In vivo Metastatic Potential in Pancreatic Adenocarcinoma
Liau, S., Jazag, A., & Whang, E. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1460 · Cited by 99
Retracted
Cationic lipid-mediated nucleic acid delivery: beyond being cationic
Rao, N. M. (2010) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2010.01.001 · Cited by 98
MicroRNAs
Barringhaus, K. G., & Zamore, P. D. (2009) · Circulation · doi:10.1161/circulationaha.107.715839 · Cited by 100
Synthetic Gene Transfer Vectors II: Back to the Future.
Behr, J. (2012) · Accounts of Chemical Research · doi:10.1021/ar200213g · Cited by 98
Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides
Moss, K. H., Popova, P. G., Hadrup, S. R., Astakhova, K., & Taskova, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01290 · Cited by 101
‘Passive’ nanoparticles for organ-selective systemic delivery: design, mechanism and perspective
Fu, L., Zhang, Y., Farokhzad, R. A., Mendes, B. B., Conde, J., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00998f · Cited by 100
Targeting Focal Adhesion Kinase With Small Interfering RNA Prevents and Reverses Load-Induced Cardiac Hypertrophy in Mice
Clemente, C. F. M. Z., Tornatore, T. F., Theizen, T. H., Deckmann, A. C., Pereira, T. C., Lopes‐Cendes, Í., Matos‐Souza, J. R., & Franchini, K. G. (2007) · Circulation Research · doi:10.1161/circresaha.107.160978 · Cited by 99
Targeting of XIAP Combined with Systemic Mesenchymal Stem Cell-Mediated Delivery of sTRAIL Ligand Inhibits Metastatic Growth of Pancreatic Carcinoma Cells
Mohr, A., Albarenque, S. M., Deedigan, L., Yu, R., Reidy, M., Fulda, S., & Zwacka, R. M. (2010) · Stem Cells · doi:10.1002/stem.533 · Cited by 100
pH-Responsive Polymeric siRNA Carriers Sensitize Multidrug Resistant Ovarian Cancer Cells to Doxorubicin via Knockdown of Polo-like Kinase 1
Benoit, D. S. W., Henry, S. M., Shubin, A. D., Hoffman, A. S., & Stayton, P. S. (2010) · Molecular Pharmaceutics · doi:10.1021/mp9002255 · Cited by 97
On the size-regulation of RNA-loaded lipid nanoparticles synthesized by microfluidic device
Okuda, K., Sato, Y., Iwakawa, K., Sasaki, K., Okabe, N., Maeki, M., Tokeshi, M., & Harashima, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.017 · Cited by 100
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs
Spänkuch, B., Kurunci‐Csacsko, E., Kaufmann, M., & Strebhardt, K. (2007) · Oncogene · doi:10.1038/sj.onc.1210355 · Cited by 96
Non-viral siRNA delivery to the lung
Thomas, M., Lu, J. J.-Q., Chen, J., & Klibanov, A. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.003 · Cited by 95
Nanomedicine-based strategies for treatment of atherosclerosis
Schiener, M., Hossann, M., Viola, J. R., Ortega‐Gómez, A., Weber, C., Lauber, K., Lindner, L. H., & Soehnlein, O. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.12.001 · Cited by 94
Synthesis, Characterization, and in Vivo Delivery of siRNA-Squalene Nanoparticles Targeting Fusion Oncogene in Papillary Thyroid Carcinoma
Raouane, M., Desmaële, D., Gilbert-Sirieix, M., Gueutin, C., Zouhiri, F., Bourgaux, C., Lepeltier, É., Gref, R., Salah, R. B., Clayman, G. L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000272 · Cited by 93
Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract
Kriegel, C., Attarwala, H. Z., & Amiji, M. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.11.003 · Cited by 94
Tivanisiran, a novel siRNA for the treatment of dry eye disease
Moreno‐Montañés, J., Bleau, A., & Jiménez, A. I. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1457647 · Cited by 93
“Briefly, siRNAs are able to enter the cells by endocytosis, once inside the cytoplasm, siRNAs undergo cellular processing in which the doublestranded RNA is split into a sense and an anti-sense strand [28,29].”
Background
Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA
Tagami, T., Uehara, Y., Moriyoshi, N., Ishida, T., & Kiwada, H. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.12.013 · Cited by 95
Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2
Lee, Y.-H., Seo, D., Choi, K., Andersen, J. B., Won, M.-A., Kitade, M., Gómez-Quiroz, L. E., Judge, A. D., Marquardt, J. U., Raggi, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3531 · Cited by 93
Development of RNAi technology for targeted therapy — A track of siRNA based agents to RNAi therapeutics
Zhou, Y., Zhang, C., & Liang, W. P. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.044 · Cited by 94
Chemistry and formulations for siRNA therapeutics
Gallas, A., Alexander, C., Davies, M. C., Puri, S., & Allen, S. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35520a · Cited by 93
Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer
Bullock, M. D., da Silva, A. M., Kanlikilicer, P., Filant, J., Rashed, M. H., Sood, A. K., Lopez‐Berestein, G., & Călin, G. A. (2015) · Non-Coding RNA · doi:10.3390/ncrna1010053 · Cited by 92
“However, enthusiasm for RNA based drugs is constrained by recognition that safe and effective mechanisms of delivering therapeutic cargos to target tissues are currently lacking [12].”
Background
Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA
Han, S., KANG, H., Shim, G., Suh, M. S., Kim, S. H., Kim, J., & Oh, Y. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.11.026 · Cited by 92
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
siRNA Delivery: From Lipids to Cell‐penetrating Peptides and Their Mimics
Gooding, M., Browne, L., Quinteiro, F. M., & Selwood, D. L. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12052 · Cited by 91
Conjugation Chemistry through Acetals toward a Dextran-Based Delivery System for Controlled Release of siRNA
Cui, L., Cohen, J. L., Chu, C. K., Wich, P. R., Kierstead, P. H., & Fréchet, J. M. J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305552u · Cited by 91
RNAi-Mediated Silencing of Myc Transcription Inhibits Stem-like Cell Maintenance and Tumorigenicity in Prostate Cancer
Civenni, G., Malek, A. V., Albino, D., García‐Escudero, R., Napoli, S., Marco, S. D., Pinton, S., Sarti, M., Carbone, G. M., & Catapano, C. V. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0615 · Cited by 92
Comprehensive Mechanism of Gene Silencing and Its Role in Plant Growth and Development
El‐Sappah, A. H., Yan, K., Huang, Q., Islam, M. M., Li, Q., Wang, Y., Khan, M. S., Xianming, Z., Mir, R. R., Li, J., et al. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.705249 · Cited by 95
Durable Protection from Herpes Simplex Virus-2 Transmission Following Intravaginal Application of siRNAs Targeting Both a Viral and Host Gene
Wu, Y., Navarro, F., Lal, A., Basar, E., Pandey, R. K., Manoharan, M., Feng, Y., Lee, S. J., Lieberman, J., & Palliser, D. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2008.12.003 · Cited by 91
“Intravenously administered chol-siRNAs are taken up by liver and jejeunal cells and silence apolipoprotein B gene expression to reduce cholesterol levels in mice and monkeys (Soutschek et al., 2004; Zimmermann et al., 2006).”
Background
N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver
Wang, H., Xiong, M., Wang, Y., Zhu, J., & Wang, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.017 · Cited by 90
Amine-reactive pyridylhydrazone-based PEG reagents for pH-reversible PEI polyplex shielding
Fella, C., Walker, G. F., Ogris, M., & Wagner, E. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.05.004 · Cited by 93
Evolution of nanomedicine formulations for targeted delivery and controlled release
Puri, S., Mazza, M., Roy, G., England, R., Zhou, L., Nourian, S., & Subramony, J. A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114962 · Cited by 94
Copolymer of poly(ethylene glycol) and poly( l -lysine) grafting polyethylenimine through a reducible disulfide linkage for siRNA delivery
Li, J., Cheng, D., Yin, T., Chen, W., Lin, Y., Chen, J., Li, R., & Shuai, X. (2013) · Nanoscale · doi:10.1039/c3nr05024f · Cited by 90
The road toward microRNA therapeutics
Seto, A. G. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.03.003 · Cited by 91
Formulation Approaches to Short Interfering RNA and MicroRNA: Challenges and Implications
Guzman‐Villanueva, D., El-sherbiny, I. M., Herrera‐Ruiz, D., Vlassov, A. V., & Smyth, H. D. C. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23300 · Cited by 90
Synthetic Nucleic Acid Delivery Systems: Present and Perspectives
Draghici, B., & Ilies, M. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500330k · Cited by 90
“lipid DLinDMA 65c were effective in vivo to silence apolipoprotein B in non-human primates.(144) Tekmira and Alnylam introduced biodegrable procationic lipids having ketal units linked to procationic dimethylamine via a methylene spacer of different lengths, such as DLinKC2-DMA 66a and congeners, which were previously…”
Background
Recent Advances in Endogenous and Exogenous Stimuli-Responsive Nanocarriers for Drug Delivery and Therapeutics
Hatakeyama, H. (2017) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00068 · Cited by 90
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo
Lee, J. B., Zhang, K., Tam, Y. Y. C., Tam, Y. K., Belliveau, N. M., Sung, V. Y. C., Lin, P. J. C., LeBlanc, E., Ciufolini, M. A., Rennie, P. S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27361 · Cited by 91
Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function
Ramezanpour, M., Schmidt, M. L., Bodnariuc, I., Kulkarni, J. A., Leung, S. S. W., Cullis, P. R., Thewalt, J. L., & Tieleman, D. P. (2019) · Nanoscale · doi:10.1039/c9nr02297j · Cited by 88
Toxicological and Pharmacokinetic Properties of QPI-1007, a Chemically Modified Synthetic siRNA Targeting Caspase 2 mRNA, Following Intravitreal Injection
Solano, E. C. R., Kornbrust, D. J., Beaudry, A. A., Foy, J. W.-D., Schneider, D. J., & Thompson, J. D. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0489 · Cited by 87
“Particularly effective is the introduction of 2 ¢ -O-methyl-modiﬁed nucleotides into the siRNA (Kariko et al., 2004; Judge et al., 2006; Zimmermann et al., 2006; Cekaite et al., 2007).”
Polymeric Nucleic Acid Vehicles Exploit Active Interorganelle Trafficking Mechanisms
Fichter, K. M., Ingle, N. P., McLendon, P. M., & Reineke, T. M. (2012) · ACS Nano · doi:10.1021/nn304218q · Cited by 86
“size and can accommodate a variety of nucleic acids,(7) and recent clinical work has shown they are well tolerated.(4,8,9) A wide variety of nonviral”
RNAi and Gene Therapy: A Mutual Attraction
Grimm, D., & Kay, M. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.473 · Cited by 86
Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors
Wen, Y., & Meng, W. S. (2014) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-014-9183-4 · Cited by 86
“apoB-specific siRNA encapsulated in stable nucleic acid-lipid particles (SNALP) reduced both apoB mRNA and protein in cynomolgus monkey by 80 % [20].”
Background
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
Kalita, T., Dezfouli, S. A., Pandey, L. M., & Uludağ, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112520 · Cited by 90
The Business of RNAi Therapeutics
Haussecker, D. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.007 · Cited by 87
The Hsp110 Molecular Chaperone Stabilizes Apolipoprotein B from Endoplasmic Reticulum-associated Degradation (ERAD)
Hrizo, S., Gusarova, V., Habiel, D. M., Goeckeler-Fried, J. L., Fisher, E. A. A., & Brodsky, J. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705216200 · Cited by 86
Ligand‐Targeted Delivery of Small Interfering RNAs to Malignant Cells and Tissues
Thomas, M., Kularatne, S. A., Qi, L., Kleindl, P. J., Leamon, C. P., Hansen, M. J., & Low, P. S. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04977.x · Cited by 85
Liposome-siRNA-Peptide Complexes Cross the Blood-Brain Barrier and Significantly Decrease PrPC on Neuronal Cells and PrPRES in Infected Cell Cultures
Pulford, B., Reim, N., Bell, A., Veatch, J., Forster, G., Bender, H., Meyerett, C., Hafeman, S., Michel, B., Johnson, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011085 · Cited by 85
“Complexing or encapsulating siRNA with liposomes has been shown to protect siRNA from degradation and improve delivery through the vasculature [29,30,31,32,33,34].”
Background
Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics
Hyeon, L. S., Kang, Y. Y., Jang, H.-E., & Mok, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.009 · Cited by 89
Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor
Ming, X., Alam, M. R., Fisher, M. H., Yan, Y., Chen, X. S., & Juliano, R. L. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq534 · Cited by 85
Biomaterials in siRNA Delivery: A Comprehensive Review
Ho, W., Zhang, X., & Xu, X. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600418 · Cited by 85
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
Bionanoparticles in cancer imaging, diagnosis, and treatment
Li, Y., Bao, Q., Yang, S., Yang, M., & Mao, C. (2022) · Open Research (University of Surrey) · doi:10.1002/viw.20200027 · Cited by 85
TGFβ signaling pathways in human health and disease
Chen, P., Qin, L., & Simons, M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1113061 · Cited by 89
“, were able to use a LNP to systemically deliver a small double-stranded RNA fragments (siRNA) to non-human primates (NHPs) (Zimmermann et al., 2006; Akinc et al., 2008).”
Background
Lipid-based vectors for siRNA delivery
Zhang, S., Zhi, D., & Huang, L. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.719232 · Cited by 83
Click-Modified Anandamide siRNA Enables Delivery and Gene Silencing in Neuronal and Immune Cells
Willibald, J., Harder, J., Sparrer, K. M. J., Conzelmann, K., & Carell, T. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303251f · Cited by 82
In vivo siRNA delivery with dendritic poly( l -lysine) for the treatment of hypercholesterolemia
Watanabe, K., Harada‐Shiba, M., Suzuki, A., Gokuden, R., Kurihara, R., Sugao, Y., Mori, T., Katayama, Y., & Niidome, T. (2009) · Molecular BioSystems · doi:10.1039/b900880b · Cited by 86
Nucleic Acid Nanocapsules for Enzyme-Triggered Drug Release
Awino, J. K., Gudipati, S., Hartmann, A. K., Santiana, J. J., Cairns‐Gibson, D. F., Gomez, N., & Rouge, J. L. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b13087 · Cited by 80

Authors: Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H.-P., & MacLachlan, I.
Affiliations: Alnylam Pharmaceuticals (United States) (US)
Electronic Arts (Canada) (CA)
Corresponding author: Zimmermann, Tracy S.
MacLachlan, Ian
ORCID: Lee, Amy C. H.
Fedoruk, Matthew N.
Harborth, Jens
Heyes, James A.
Lam, Kieu
McClintock, Kevin
Palmer, Lorne R.
Manoharan, Muthiah
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2006-03-26
Volume: 441
Issue: 7089
Pages: 111-114
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature04688
OpenAlex: W2095151181
Cited by: 1,357
References: 20
Citations by year: 2026: 21 · 2025: 22 · 2024: 30 · 2023: 42 · 2022: 40 · 2021: 35 · 2020: 35 · 2019: 46 · 2018: 30 · 2017: 47 · 2016: 54 · 2015: 70 · 2014: 97 · 2013: 113 · 2012: 111
FWCI: 46.06
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Alnylam Pharmaceuticals
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: RNA interference, gene silencing, siRNA, apolipoprotein B, siRNA therapeutics, systemic siRNA delivery, Macaca fascicularis, non-human primates, hypercholesterolemia, LDL cholesterol, B-cell lymphoma, CARD11
MeSH terms: Animals, Apolipoproteins B, Phenotype, Primates, RNA, Messenger, RNA Interference, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RNAi-mediated gene silencing in non-human primates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks